Did you know?

Pacific Biosciences of California's (PACB) CEO Mike Hunkapiller on Q4 2015 Results - Earnings Call Transcript SA Transcripts Wed, Feb. 03, 2016 Pacific Biosciences of California (PACB) Q4 2015 ...Nov 29, 2023 · See the latest Pacific Biosciences of California Inc stock price (PACB:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Pacific Biosciences of California Inc. published this content on 15 November 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 15 November 2022 20:01:02 UTC .Complete Pacific Biosciences of California Inc. stock information by Barron's. View real-time PACB stock price and news, along with industry-best analysis.Pacific Biosciences of California has been profitable 1 over the past 10 years. Over the past twelve months, the company had a revenue of $146.10 million and Loss Per Share of $1.35.Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a California-based biotech firm founded in 2004. It is ranked seventh on our list of 10 best biotech stocks to buy according to Cathie Wood.Currently, the analyst consensus on Pacific Biosciences is a Hold with an average price target of $11.40. See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $14.20 and a ...Pacific Biosciences of California, Inc. : News, information and stories for Pacific Biosciences of California, Inc. | Nasdaq: PACB | Nasdaq e5.obVqkYPOfJNKrd0Co_B5cEDheThrH58M33b_WYEND74.y-ES3Pr9L_cB-O5L7oYeOAiCA1UAWNt8kke9KdZaes-U4i_J76wr1xDpiAHENRY CHRISTIAN O, the of Pacific Biosciences of California Inc, sale 96,844 shares at $10.12 during a trade that took place back on Sep 18, which means that HENRY CHRISTIAN O is holding 1,106,095 shares at $980,255 based on the most recent closing price. Stock Fundamentals for PACB. Current profitability levels for the company …Nov 15, 2022 · Pacific Biosciences of California Inc. published this content on 15 November 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 15 November 2022 20:01:02 UTC . Biotech stock Pacific Biosciences could return 50% in 12 months: TD Cowen. Pacific Biosciences of California Inc (NASDAQ: PACB) is trading meaningfully up on Friday after a TD Cowen analyst turned super bullish on the biotechnology company. Pacific Biosciences stock has upsi...Pacific Biosciences of California, Inc. beats earnings expectations. Reported EPS is $-0.26, expectations were $-0.3. Operator: Good afternoon, everyone, and welcome to the PacBio Third Quarter ...Get the latest PACB stock quote, charts, news, and other financial information to help you make more informed trading and investment decisions. See the company's earnings, balance sheet, cash flow, and market cap for the second quarter of 2023.View Pacific Biosciences of California, Inc PACB investment & stock information. Get the latest Pacific Biosciences of California, Inc PACB detailed stock quotes, stock data, Real-Time ECN, charts ...Discover Pacific Biosciences of California's earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers. ... Independent Director exercised options and sold US$793k worth of stock May 29. The Pullback In Pacific Biosciences Makes For A Much More Interesting Opportunity …Let’s take a look at how Pacific Biosciences of California Inc’s stock performed this quarter. Earnings: $-0.28 per share, versus the consensus estimate of $-0.32 per share, according to AAII’s Stock Investor Pro, Refinitiv and I/B/E/S. Revenue: $39 million, versus $33 million in the same period one year ago.Pacific Biosciences of California Stock Forecast and Price Target. Year-long price target forecasts from four prominent analysts have recently been released for Pacific Biosciences of California, with an average price target of $10.50. This potential gain of 24.41 percent from the previous closing price in November, 2023 is calculated on …The stock price of Pacific Biosciences of California, a biotechnology company that develops gene sequencing systems, has seen a large fall of 38% over the …Oct 30, 2023 · Oct. 30, 2023, 04:07 PM. (RTTNews) - Pacific Biosciences of California, Inc. (PACB) released Loss for third quarter that decreased from the same period last year and beat the Street estimates. The ... Nov 29, 2023 · See the latest Pacific Biosciences of California Inc stock price (PACB:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Traveling by car offers a sense of freedom and adventure that is hard to replicate with other modes of transportation. The Pacific Coast Highway, also known as Highway 1, stretches for over 600 miles along the stunning coastline of Californ...MENLO PARK, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB)(“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, highly accurate sequencing platforms, today announced a partnership with The European Reference Genome Atlas (ERGA) consortium to support …Pacific Biosciences of California (PACB) Q4 2021 Earnings Call Transcript PACB earnings call for the period ending December 31, 2021. Motley Fool Transcribing | Feb 16, 2022 According to 6 analyst offering 12-month price targets in the last 3 months, Pacific Biosciences has an average price target of $14.67 with a high of $17.00 and a low of $12.00. Below is a summary ...In other news, insider Susan G. Kim sold 19,257 shares of PacificSo what. Softbank subsidiary SB Management will purchase $900 mi Pacific Biosciences (PACB) delivered earnings and revenue surprises of 6.06% and 10.55%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? Traveling by car offers a sense of freedom and adventure that Pacific Biosciences of California Inc stock received a consensus recommendation rating of an Overweight, based on a mean score of 1.58. If we narrow it down even further, the data shows that 0 out of 12 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 3 recommended PACB as a Hold, whereas 8 …Institutional investors purchased a net $7.8 million shares of PACB during the quarter ended June 2019 and now own 98.90% of the total shares outstanding. This ... A high-level overview of Pacific Biosciences of California, Inc. (PACB

Pacific Biosciences of California Inc (NASDAQ:PACB)’s traded shares stood at 3.89 million during the last session, with the company’s beta value hitting 1.76. At the close of trading, the stock’s price was $8.36, to imply an increase of 0.97% or $0.08 in intraday trading.(RTTNews) - Pacific Biosciences of California, Inc. (PACB) reported Loss for second quarter that decreased from the same period last year and beat the Street estimates. The company's bottom line ...PacBio Announces Third Quarter 2023 Financial Results. MENLO PARK, Calif., Oct. 30, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2023. Third quarter results Revenue of $55.7 million, a 72% increase…. Read more.Nov 29, 2023

The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings. Price Target Upside/Downside. According to ...PacBio Also Closes $300 Million PIPE Financing in Support of Transaction. MENLO PARK, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or “PacBio”), a leading provider of high-quality, long-read sequencing platforms, and Omniome, a San Diego-based ……

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Nov 15, 2023 · Get Pacific Biosciences of Calif. Possible cause: HENRY CHRISTIAN O, the of Pacific Biosciences of California Inc, sale 96,844 shares at $.